about
Current role of transient elastography in the management of chronic hepatitis B patientsPlatelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosisG0/G1 switch gene 2 has a critical role in adipocyte differentiation.Nuclear receptor PPARγ-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosisCaffeine inhibits adipogenesis through modulation of mitotic clonal expansion and the AKT/GSK3 pathway in 3T3-L1 adipocytesDexras1 links glucocorticoids to insulin-like growth factor-1 signaling in adipogenesis.Suppression of PPARγ-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis.Dexras1 mediates glucocorticoid-associated adipogenesis and diet-induced obesity.Monoacylglycerol O-acyltransferase 1 is regulated by peroxisome proliferator-activated receptor γ in human hepatocytes and increases lipid accumulation.Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment.Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CRemaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South KoreaAromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort StudyPrediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovirExtremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase
P50
Q30358894-1CF1937A-BCDA-44E6-88D6-9FD46FAF370EQ33889261-94F686A2-FD7A-4732-B6ED-A1193FFD5615Q34393763-32002A01-5ED8-4B83-ADD1-EB0B871CD49AQ36187402-2BDC9D60-97E7-478E-A116-54D62582BA85Q37024459-6F6E1B0A-2C1D-42DC-835D-975496395B5AQ37039927-3C8E2DA1-4A02-44FB-9D4B-75CDD1DD2512Q37086815-25A80B9F-ED66-4520-B754-2AEDBF4D0E05Q37409317-69D5EA20-D9E8-4D44-AFCD-E58BA07F3A85Q38300018-D25F2A2A-E4C2-4241-8FBE-8FBE96FCFD9EQ40061404-BA7CF45F-9823-4CC1-B8E8-92DE42148ECFQ41521289-428F4B8F-C276-4F20-9542-CE07FADF4E66Q57210442-451AFCE4-CE62-4C80-A7A5-A6787E644B6DQ91210102-C52D4F32-191D-4156-B869-016B977EA534Q91266568-8862CBA3-E061-4610-9544-253C93340C98Q95840086-8829F4BB-843F-46DC-84B1-A890C96965B5
P50
description
investigador
@es
researcher
@en
name
Jung Hwan Yu
@en
type
label
Jung Hwan Yu
@en
prefLabel
Jung Hwan Yu
@en
P31
P496
0000-0001-5672-038X